Market Overview

UPDATE: Credit Suisse Upgrades St. Jude Medical to Outperform on Durata Outlook

Related STJ
St. Jude Confirms 5-Year Data from FAME Trial Further Confirms Sustained, Long Term Benefit of FFR-Guided PCI
Benzinga's M&A Chatter for Thursday August 27, 2015
St. Jude Medical's Leadless II & FAME Trial Results Positive (Zacks)

Credit Suisse upgraded St. Jude Medical (NYSE: STJ) from Neutral to Outperform and raised the price target from $43.00 to $48.00.

Credit Suisse noted, "Since Riata (STJ's recalled defib lead) failure reports began to circulate widely in 8/10, concerns about Durata's reliability (STJ's current defib lead) have weighed on STJ's valuation. While Durata concerns are likely to persist near-term, we came away from STJ's investor day impressed by the company's confidence in Durata and its optimism about the May HRS conference where STJ expects to see multiple favorable Durata studies."

St. Jude Medical closed at $41.17 on Friday.

Latest Ratings for STJ

Aug 2015Credit SuisseAssumesOutperform
Jul 2015Deutsche BankDowngradesBuyHold
Jul 2015BMO CapitalDowngradesOutperformMarket Perform

View More Analyst Ratings for STJ
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Upgrades Analyst Ratings


Related Articles (STJ)

View Comments and Join the Discussion!

Get Benzinga's Newsletters